Evidence map›Paper›PMID 35766997›Full record

ArticleGenes, chromosomes & cancer2022

Recurrent VGLL3 fusions define a distinctive subset of spindle cell rhabdomyosarcoma with an indolent clinical course and striking predilection for the head and neck.

Abbas Agaimy, Josephine K Dermawan, Iona Leong, Robert Stoehr, David Swanson, Ilan Weinreb, Lingxin Zhang, Cristina R Antonescu, Brendan C Dickson

Open access · hybridAbstract read
In one paragraph

Article in Genes, chromosomes & cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

  1. EWSR1::ATF7 fusion driven mesenchymal neoplasm with rhabdomyoblastic differentiation.Virchows Archiv : an international journal of pathology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Clinicopathologic and Molecular Genetic Features of Spindle Cell Rhabdomyosarcoma Harboring ZFP64::NCOA2/3 Fusions: A Series of 14 Cases.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Article
  6. Targeting the Hippo pathway in cancer.Nature reviews. Drug discovery · 2025
    Review
  7. Beyond Hybrid Morphology: A Large Series of Fusion-Driven Benign Peripheral Nerve Sheath Tumors Including 5 Tumors With Novel Fusions.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Molecular pathology in diagnosis and prognostication of head and neck tumors.Virchows Archiv : an international journal of pathology · 2024
    Review
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Abbas AgaimyInstitute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.ORCID 0000-0002-0445-8161
Josephine K DermawanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-1139-2914
Iona LeongFaculty of Dentistry, University of Toronto, Toronto, Ontario, Canada.
Robert StoehrInstitute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
David SwansonDepartment of Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
Ilan WeinrebDepartment of Pathobiology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-9552-3549
Lingxin ZhangDepartment of Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0001-5086-2272
Cristina R AntonescuDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-9717-8205
Brendan C DicksonDepartment of Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0003-2269-6216
Mount Sinai Hospital · CAFriedrich-Alexander-Universität Erlangen-Nürnberg · DEMemorial Sloan Kettering Cancer Center · USUniversity Health Network · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2018 to 2026
$21.5M
SPORE in Soft Tissue SarcomaP50CA140146 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SPRIGGS, DAVID R · 2010 to 2014
$11.1M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA140146NCI NIH HHS P50 CA217694
6 · The paper itself

Abstract

The mammalian Vestigial-like (VGLL) transcriptional cofactor family of proteins VGLL1-4 has recently emerged as an important player in the tumorigenesis of diverse neoplasms. The role of VGLL3 in soft tissue tumors is exemplified by its amplification in myxoinflammatory fibroblastic sarcoma and its rearrangement (fused to CHD7, CHD9, or MAMLD1) in hybrid schwannoma-perineurioma. This study characterizes a distinctive low-grade myogenic neoplasm with a striking predilection for the head and neck, characterized by VGLL3 fusions. The study includes five males and one female patient, aged 30-71 years (median, 56). Three tumors originated in the tongue, with one case each in the nasopharynx, oral cavity, and oropharynx. The VGLL3 fusion partners included TCF12 (n = 3), EP300 (n = 2), and PPARGC1A (n = 1). The tumor size range was 0.8-1.6 cm (all, but one, was <1 cm). Histologically, all tumors displayed bland spindle to ovoid cells arranged into vague fascicular and diffuse patterns. Mitotic activity ranged from 1 to 7 per 10 HPFs. Five tumors were muscle-centered and infiltrative, and one was centered beneath nasopharyngeal mucosa. Immunohistochemistry revealed consistent expression of desmin (diffuse in four and patchy in two cases) associated with patchy smooth muscle actin expression (4/6), and focal reactivity for myogenin (5/6) and myoD1 (1/3). All patients were managed surgically; one patient each received adjuvant radio- or chemotherapy. Three patients with follow-up were without disease at 8, 19, and 60 months and one was alive with unknown disease status at 24 months. All VGLL3 fusions were in-frame and involved exon 2, fused with either TCF12 exon 16, EP300 exon 31, or PPARGC1A exon 5, respectively. This series characterizes a distinctive subset of spindle cell rhabdomyosarcoma (RMS) with a predilection for the head and neck in adults, defined by VGLL3 fusions, likely indolent behavior and limited rhabdomyoblastic differentiation. Further delineation of this entity and differentiation from more aggressive molecular subtypes of spindle cell RMS is mandatory to define the most appropriate therapeutic strategy and avoid overtreatment.

Indexed as

RhabdomyosarcomaSoft Tissue NeoplasmsTranscription FactorsActinsAdultAgedBiomarkers, TumorDesminDNA-Binding ProteinsFemaleHumansMaleMiddle AgedMyogeninActinsBiomarkers, TumorDesminDNA-Binding ProteinsMyogeninTranscription FactorsVGLL1 protein, humanVGLL3 protein, humanEP300gene fusionhead and neckPPARGC1Asarcomaspindle cell rhabdomyosarcomaTCF12VGLL3

Identifiers

PMID35766997
PMCPMC10243299
OpenAlexW4283734283

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.